Credit: Shutterstock. Study participants suffered from chronic back pain for an average of 12.8 years. The Food and Drug Administration (FDA) has expanded the approval of Abbott’s spinal cord ...

24-month interim results from the first long-term study of SCS with automatic, objective, daily remote monitoring presented at NANS 2025 Annual Meeting This system integrates RESONANCE™ multiphase ...

“The approval of the Proclaim Elite recharge-free SCS system is a needed advancement for both patients and physicians who now have access to a low-maintenance chronic pain treatment that can reduce ...

Nevro is a company dedicated to the design and manufacture of medical devices. I believe that further news about the efficacy of the product, sufficient marketing, and internationalization efforts ...

LAS VEGAS, Nev.--(BUSINESS WIRE)--During the scientific sessions at the 16 th Annual NANS Conference, Dr. Liong Liem, Anesthesiologist at Sint Antonius Ziekenhuis in the Netherlands and member of the ...

At Three-Months, 80% of Patients Treated with DTM SCS Reported Back Pain Reliefof at Least 50%; 63% Reported Profound Back Pain Relief of 80% or Greater1 The RCT demonstrated profound pain relief and ...

DUBLIN, Aug. 25, 2023 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, has received CE (Conformité Européenne) Mark approval for its Inceptiv™ closed-loop ...